PT  - JOURNAL ARTICLE
AU  - Spick, Matt
AU  - Longman, Katie
AU  - Frampas, Cecile
AU  - Costa, Catia
AU  - Walters, Deborah Dunn
AU  - Stewart, Alex
AU  - Wilde, Mike
AU  - Greener, Danni
AU  - Evetts, George
AU  - Trivedi, Drupad
AU  - Barran, Perdita
AU  - Pitt, Andy
AU  - Bailey, Melanie
TI  - Changes to the sebum lipidome upon COVID-19 infection observed via non-invasive and rapid sampling from the skin
AID  - 10.1101/2020.09.29.20203745
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.29.20203745
4099  - http://medrxiv.org/content/early/2020/09/29/2020.09.29.20203745.short
4100  - http://medrxiv.org/content/early/2020/09/29/2020.09.29.20203745.full
AB  - The COVID-19 pandemic has led to an urgent and unprecedented demand for testing – both for diagnosis and prognosis. Here we explore the potential for using sebum, collected via swabbing of a patient’s skin, as a novel sampling matrix to fulfil these requirements. In this pilot study, sebum samples were collected from 67 hospitalised patients (30 PCR positive and 37 PCR negative). Lipidomics analysis was carried out using liquid chromatography mass spectrometry. Total fatty acid derivative levels were found to be depressed in COVID-19 positive participants, indicative of dyslipidemia. Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA) modelling showed promising separation of COVID-19 positive and negative participants when comorbidities and medication were controlled for. Given that sebum sampling is rapid and non-invasive, this work may offer the potential for diagnostic and prognostic testing for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors would like to acknowledge funding from the EPSRC Impact Acceleration Account for sample collection, as well as EPSRC Fellowship Funding EP/R031118/1. Mass Spectrometry was funded under EP/P001440/1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this project (IRAS project ID 155921) was obtained via the NHS Health Research Authority (REC reference: 14/LO/1221)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis work took place as part of the COVID-19 MS Coalition and all data will be stored and fully accessible on the MS Coalition open repository.